HALOZYME THERAPEUTICS, INC.
HALOOther · Large accelerated filer · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.3M | $660.1M | $443.3M | $267.6M |
| Operating income | $469.0M | $551.5M | $337.6M | $267.5M | $275.9M | $144.3M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M | $129.1M |
| Total assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B | $579.9M |
| Total liabilities | $2.48B | $1.70B | $1.65B | $1.67B | — | — |
| Equity | $48.8M | $363.8M | $83.8M | $169.8M | $197.0M | $151.0M |
| EPS (diluted) | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 |
| Shares out. | 123.2M | 126.8M | 135.4M | 137.7M | 135.3M | 138.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 33.6%
- Net margin
- 22.7%
- Return on equity
- 649.2%
- Return on assets
- 12.5%
- Return on capital (ROCE)
- 20.0%
- Liabilities / assets
- 98.1%
- Debt / equity
- 50.73×
- Book value / share
- $0.40
- Revenue growth (YoY)
- 37.6%
- Net income growth (YoY)
- −28.6%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.02safe
- Accruals / assets
- −13.3%clean
- Beneish M-Score
- -2.57normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 6 good- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Torley HelenOfficer — PRESIDENT AND CEO | May 11, 2026 | Option exercise | 20,000 | $12.07 |
| Posard Matthew L.Director | May 5, 2026 | Grant | 3,796 | $0.00 |
| Krishnan MaheshDirector | May 5, 2026 | Grant | 3,796 | $0.00 |
| Lang James PaulDirector | May 5, 2026 | Grant | 3,796 | $0.00 |
| Henderson Jeffrey WilliamDirector | May 5, 2026 | Grant | 3,796 | $0.00 |
| Duncan Barbara GayleDirector | May 5, 2026 | Grant | 3,796 | $0.00 |
| Connaughton BernadetteDirector | May 5, 2026 | Grant | 6,796 | $0.00 |
| Connaughton BernadetteDirector | May 1, 2026 | Sell | 1,625 | $63.48 |
| Torley HelenOfficer — PRESIDENT AND CEO | Apr 6, 2026 | Option exercise | 10,000 | $12.07 |
| Torley HelenOfficer — PRESIDENT AND CEO | Apr 1, 2026 | Option exercise | 20,000 | $12.07 |
| Caudill CortneyOfficer — SVP, CHIEF OPERATING OFFICER | Mar 9, 2026 | Option exercise | 20,000 | $33.51 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 13.4M | 6.7 | -6.9% |
| Apr 30, 2026 | 14.4M | 10.2 | +0.9% |
| Apr 15, 2026 | 14.3M | 10.6 | +1.5% |
| Mar 31, 2026 | 14.0M | 9.4 | +2.5% |
| Mar 13, 2026 | 13.7M | 8.4 | +1.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 11, 2026
- Shareholder voteMay 7, 2026
- Director / officer changeApr 30, 2026
- Amended charter or bylawsApr 24, 2026
- Director / officer changeMar 12, 2026
- Results of operationsFeb 17, 2026
- Results of operationsJan 28, 2026
- Director / officer changeDec 9, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.